Fosun Pharma and BioNTech have announced their intention to supply 10 million doses of mRNA new crown vaccine to Hong Kong and Macao.

BioNTech and Shanghai Fosun Pharmaceuticals (Group) Co., Ltd. jointly announced that, based on the current agreement on supply cooperation, 10 million doses of the new mRNA crown vaccine developed by BioNTech will be supplied to the Hong Kong Special Administrative Region of China and the Macao Special Administrative Region of China after clinical trials have confirmed the safety and effectiveness of the BNT162 candidate vaccine and obtained regulatory approval.
sean Marett, chief business and commercial officer at BioNTech, said, "The potential partnership announced is the first time BioNTech and partner Fosun Pharma have supplied BioNTech-developed vaccines to the Chinese market.
further demonstrate BioNTech's commitment to providing its mRNA candidate vaccine globally and to preventing the spread of the new crown outbreak.
, Vice President of Fosun Pharma, said, "We look forward to the introduction of safe and effective new crown vaccine products as soon as possible, so as to effectively prevent the spread of the new crown pneumonia epidemic around the world."
Fosun Pharma will make full use of its global advantages, as well as the resources and marketing network advantages in China's domestic market, to improve the access of vaccine products, to contribute to the global fight against the new crown epidemic.
"Fosun Industrial (Hong Kong) Co., Ltd., a wholly owned subsidiary of Fosun Pharmaceuticals, signed a letter of intent for the vaccine distribution cooperation with Hong Kong Jacobson Research Pharmaceutical Co., Ltd. on August 27.
On August 5, 2020, Fosun Pharma and BioNTech jointly announced that BNT162b1, a candidate vaccine for the BNT162 project, had begun Phase I trials in China after obtaining clinical trial approval from the State Drug Administration of China.
.